<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39208484</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-3171</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Poultry science</Title><ISOAbbreviation>Poult Sci</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetic modeling of sulfamethoxazole-trimethoprim and sulfadiazine-trimethoprim combinations in broilers.</ArticleTitle><Pagination><StartPage>104200</StartPage><MedlinePgn>104200</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104200</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psj.2024.104200</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0032-5791(24)00779-X</ELocationID><Abstract><AbstractText>Sulfonamides (S) are old bacteriostatic antibiotics which are widely prescribed in combination with trimethoprim (TMP) for the treatment of various diseases in food-producing animals such as poultry. Nowadays, the 1:5 dose ratio of TMP/S used in broilers is a direct transposition of the ratio determined in Human decades ago for TMP/sulfamethoxazole (SMX), aiming to obtain a supposed synergistic plasma concentration ratio of 1:19. However, major pharmacokinetics (PK) differences exist according to the sulfonamide used in the combination. Here, we generated new PK data in broilers after a cross-over design with IV and the oral administration of 2 major sulfonamides, sulfadiazine (SDZ) and SMX, in combination with TMP, and analyzed the data via a population pharmacokinetic (popPK) modeling approach. Results showed that TMP has a greater plasma to tissue distribution than both sulfonamides with a higher volume of distribution (0.51 L/kg for SDZ, 0.62 L/kg for SMX and 3.14 L/kg for TMP). SMX has the highest elimination half-life (2.83 h) followed by SDZ and TMP (2.01 h and 1.49 h, respectively). The oral bioavailability of the 3 molecules was approximately 100%. Bodyweight could explain some of the inter-individual variability in the volume of distribution of SDZ and SMX and the clearance of SDZ and TMP, as heavier broilers have higher typical values. Monte Carlo simulations of a large virtual broiler population (n = 1,000) showed that the targeted plasma ratio of TMP:S of 1:19 was rarely or never reached at the individual level for both combinations at the marketed doses and greatly varies over time and between individuals, questioning the relevance of the 1:5 dose ratio for current formulations of TMP/S.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boulanger</LastName><ForeName>Marine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Therapeutic Innovations and Resistance (INTHERES), Université de Toulouse INRAE ENVT, Toulouse 31076, France; Fougères Laboratory, French Agency for Food, Environmental and Occupational Health &amp; Safety (ANSES), 10B rue Claude Bourgelat, Fougères 35306, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taillandier</LastName><ForeName>Jean-François</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Fougères Laboratory, French Agency for Food, Environmental and Occupational Health &amp; Safety (ANSES), 10B rue Claude Bourgelat, Fougères 35306, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henri</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fougères Laboratory, French Agency for Food, Environmental and Occupational Health &amp; Safety (ANSES), 10B rue Claude Bourgelat, Fougères 35306, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devreese</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathobiology, Laboratory of Pharmacology and Toxicology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, 9820, Merelbeke, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Baere</LastName><ForeName>Siegrid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathobiology, Laboratory of Pharmacology and Toxicology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, 9820, Merelbeke, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferran</LastName><ForeName>Aude A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Therapeutic Innovations and Resistance (INTHERES), Université de Toulouse INRAE ENVT, Toulouse 31076, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viel</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fougères Laboratory, French Agency for Food, Environmental and Occupational Health &amp; Safety (ANSES), 10B rue Claude Bourgelat, Fougères 35306, France. Electronic address: alexis.viel@anses.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Poult Sci</MedlineTA><NlmUniqueID>0401150</NlmUniqueID><ISSNLinking>0032-5791</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0N7609K889</RegistryNumber><NameOfSubstance UI="D013411">Sulfadiazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>AN164J8Y0X</RegistryNumber><NameOfSubstance UI="D014295">Trimethoprim</NameOfSubstance></Chemical><Chemical><RegistryNumber>39474-58-3</RegistryNumber><NameOfSubstance UI="C024873">sulfadiazine, trimethoprim drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>8064-90-2</RegistryNumber><NameOfSubstance UI="D015662">Trimethoprim, Sulfamethoxazole Drug Combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000096926">Benzenesulfonamides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002645" MajorTopicYN="Y">Chickens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013411" MajorTopicYN="Y">Sulfadiazine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014295" MajorTopicYN="Y">Trimethoprim</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015662" MajorTopicYN="Y">Trimethoprim, Sulfamethoxazole Drug Combination</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000096926" MajorTopicYN="N">Benzenesulfonamides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">combination</Keyword><Keyword MajorTopicYN="N">dosage regimen</Keyword><Keyword MajorTopicYN="N">population pharmacokinetic modeling</Keyword><Keyword MajorTopicYN="N">sulfonamide</Keyword><Keyword MajorTopicYN="N">trimethoprim</Keyword></KeywordList><CoiStatement>DISCLOSURES The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39208484</ArticleId><ArticleId IdType="pmc">PMC11399637</ArticleId><ArticleId IdType="doi">10.1016/j.psj.2024.104200</ArticleId><ArticleId IdType="pii">S0032-5791(24)00779-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baert K., Baere S.D., Croubels S. Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens. Res. Comms. 2003;27:301–309.</Citation><ArticleIdList><ArticleId IdType="pubmed">12872830</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett M., Bushby S.R.M. Trimethoprim and the sulfonamides. Vet. Rec. 1970;87:43–51.</Citation><ArticleIdList><ArticleId IdType="pubmed">5529571</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergstrand M., Hooker A.C., Wallin J.E., Karlsson M.O. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085712</ArticleId><ArticleId IdType="pubmed">21302010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bon C., Toutain P.L., Concordet D., Gehring R., Martin-Jimenez T., Smith J., Pelligand L., Martinez M., Whittem T., Riviere J.E., Mochel J.P. Mathematical modeling and simulation in animal health. Part III : Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics. Vet. Pharm. Therapeut. 2018;41:171–183.</Citation><ArticleIdList><ArticleId IdType="pubmed">29226975</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulanger M., Tchalaou S., Roques B.B., Ferran A.A., Viel A. Determination of optimal ratios for three sulfonamides/trimethoprim combinations against E.coli using checkerboard and time-kill assays. Vet. Pharm. Therapeut. 2023;46:94–95.</Citation></Reference><Reference><Citation>Bushby S.R.M. Sulfonamides and trimethoprim. J. Am. Vet. Med. Assoc. 1980;176:1049–1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">7216871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chassan M., Hémonic A., Concordet D. What matters in piglets’ exposure to antibiotics administered through drinking water? Antibiotics. 2021;10:1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8466382</ArticleId><ArticleId IdType="pubmed">34572649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Wang C.-Y., Li Z.-R., Pan Y., Liu M.-B., Jiao Z. Can population pharmacokinetics of antibiotics be extrapolated? Implications of external evaluations. Clin. Pharmacokinet. 2021;60:53–68.</Citation><ArticleIdList><ArticleId IdType="pubmed">32960439</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer P., Belpaire F.M., Debackere M., Bogaert M.G. Pharmacokinetics and protein binding of three sulfonamides in sheep. Zentralblatt für Veterinärmedizin Reihe A. 1981;28:468–474.</Citation><ArticleIdList><ArticleId IdType="pubmed">6800157</ArticleId></ArticleIdList></Reference><Reference><Citation>Dréano E., Valentin C., Taillandier J.-F., Travel A., Soumet C., Bridier A., Hurtaud-Pessel D., Laurentie M., Viel A., Mompelat S. Presence and depletion of sulfadiazine, trimethoprim and oxytetracycline into feathers of treated broiler chickens and impact on antibiotic-resistant bacteria. J. Agric. Food Chem. 2022;70:16106–16116.</Citation><ArticleIdList><ArticleId IdType="pubmed">36524955</ArticleId></ArticleIdList></Reference><Reference><Citation>EUCAST, 2017. Rationale for EUCAST clinical breakpoints. Accessed February 2024.https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Tri-su_rationale_document_1.0_170605.pdf.</Citation></Reference><Reference><Citation>European Medicines Agency. AMEG 2018 - categorisation of antibiotics in the European Union; EMA/688114/2020; 2020. Accessed February 2024.https://www.ema.europa.eu/en/documents/report/categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals_en.pdf.</Citation></Reference><Reference><Citation>European Medicines Agency, European Surveillance of Veterinary Antimicrobial Consumption, 2022. Accessed February 2024.https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-31-european-countries-2022-trends-2010-2022-thirteenth-esvac-report_en.pdf.</Citation></Reference><Reference><Citation>Ferran A.A., Lacroix M.Z., Bousquet-Mélou A., Duhil I., Roques B.B. Levers to improve antibiotic treatment of lambs via drinking water in sheep fattening houses: The example of the sulfadimethoxine/trimethoprim combination. Antibiotics. 2020;9:561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7559794</ArticleId><ArticleId IdType="pubmed">32878175</ArticleId></ArticleIdList></Reference><Reference><Citation>Garwacki S., Lewicki J., Wiechetek M., Rys S., Rutkowski J., Zaremba M. A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. J. Vet. Pharmacol. Therap. 1996;19:423–430.</Citation><ArticleIdList><ArticleId IdType="pubmed">8971670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lees P., Concordet D., Aliabadi F.S., Toutain P.-L. In: Antimicrobial resistance in bacteria of animal origin. Aarestrup F.M., editor. ASM Press; Washington, DC: 2019. Drug selection and optimization of dosage schedules to minimize antimicrobial resistance; pp. 49–71.</Citation></Reference><Reference><Citation>Löscher W., Fabbender C.P., Weissing M., Kietzmann M. Drug plasma levels following the administration of trimethoprim and sulfonamide combinations to broilers. Vet. Pharm. Therapeut. 1990;13:309–319.</Citation><ArticleIdList><ArticleId IdType="pubmed">2231873</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters P.A., O'Bryan T.A., Zurlo J., Miller D.Q., Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch. Intern. Med. 2003;163:402.</Citation><ArticleIdList><ArticleId IdType="pubmed">12588198</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen P., Rasmussen F. Half-life, apparent volume of distribution and protein-binding for some sulfonamides in cows. Res. Vet. Sci. 1977;22:205–208.</Citation><ArticleIdList><ArticleId IdType="pubmed">860094</ArticleId></ArticleIdList></Reference><Reference><Citation>Petritz O.A., Enomoto H., Meyer E.G., Thomson A., Baynes R.E., Flammer K. Pharmacokinetics and safety of sulfamethoxazole-trimethoprim after oral administration of single and multiple doses to Rhode Island red chickens (Gallus gallus domesticus) J. Avian Med. Surg. 2023;37:1–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">37358198</ArticleId></ArticleIdList></Reference><Reference><Citation>Queralt J., Castells I. Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens. Poult. Sci. 1985;64:2362–2367.</Citation><ArticleIdList><ArticleId IdType="pubmed">4095069</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter A.J. Overview. Trimethoprim-sulfamethoxazole: An assessment of more than 12 years of use. Clin. Infect. Dis. 1982;4:196–236.</Citation><ArticleIdList><ArticleId IdType="pubmed">7051224</ArticleId></ArticleIdList></Reference><Reference><Citation>Summary of product characteristics of Adjusol®. 2024. Accessed February 2024. https://medicines.health.europa.eu/veterinary/en/600000039940.</Citation></Reference><Reference><Citation>Szmolka A., Nagy B. Multidrug resistant commensal Escherichia coli in animals and its impact on public health. Front. Microbiol. 2013;4:258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759790</ArticleId><ArticleId IdType="pubmed">24027562</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Wu H., Maharaj A., Edginton A.N., Balevic S.J., Cobbaert M., Cunningham A.P., Hornik C.P., Cohen-Wolkowiez M. Physiologically based pharmacokinetic modeling for trimethoprim and sulfamethoxazole in children. Clin. Pharmacokinet. 2019;58:887–898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6586496</ArticleId><ArticleId IdType="pubmed">30840200</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeulen B., De Backer P., Remon J.P. Drug administration to poultry. Adv. Drug Deliv. Rev. 2002;54:795–803.</Citation><ArticleIdList><ArticleId IdType="pubmed">12363431</ArticleId></ArticleIdList></Reference><Reference><Citation>Viel A., Boulanger M., Taillandier J.F., Laurentie M., Henri J., Lacroix M., Ferran A.A., Roque B.B. Population PK modeling of different sulfonamides in association with trimethoprim in pigs. Vet. Pharm. Therapeut. 2023;46:82–83.</Citation></Reference><Reference><Citation>Wicha S.G., Chen C., Clewe O., Simonsson U.S. A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions. Nat. Commun. 2017;8:2129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5730559</ArticleId><ArticleId IdType="pubmed">29242552</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>